Berenice Illades-Aguiar

Prof. Berenice Illades-Aguiar

Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, Mexico
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
CNCynthia Rodríguez Nava
Cynthia Rodríguez Nava
COCarlos Ortuño-Pineda
Carlos Ortuño-Pineda
BIBerenice Illades-Aguiar
Berenice Illades-Aguiar
EFEugenia Flores-Alfaro
Eugenia Flores-Alfaro
MVMarco Antonio Leyva Vazquez
Marco Antonio Leyva Vazquez
LALuz del Carmen Alarcón-Romero
Luz del Carmen Alarcón-Romero
Monoclonal antibodies are among the most effective tools for detecting tumor-associated antigens. The U.S. Food and Drug Administration (FDA) has approved more than 36 therapeutic antibodies for developing novel alternative therapies that have significant success rates in fighting cancer. However, some functional limitations have been described, such as their access to solid tumors and low interaction with the immune system. Single-chain variable fragments (scFv) are versatile and easy to produce, and being an attractive tool for use in immunotherapy models. The small size of scFv can be advantageous for treatment due to its short half-life and other characteristics related to the structural and functional aspects of the antibodies. Therefore, the main objective of this review was to describe the current situation regarding the mechanisms of action, applications, and limitations of monoclonal antibodies and scFv in the treatment of cancer.

27 October 2010 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
DMDinorah N Martínez-Carrillo
Dinorah N Martínez-Carrillo
Elvira Garza-GonzálezElvira Garza-González
Elvira Garza-González
RBReyes Betancourt-Linares
Reyes Betancourt-Linares
TMTrinidad Mónico-Manzano
Trinidad Mónico-Manzano
CACuauhtémoc Antúnez-Rivera
Cuauhtémoc Antúnez-Rivera
GFGloria Fernández-Tilapa
Gloria Fernández-Tilapa
Background: The association between proinflammatory cytokine gene polymorphisms and gastric diseases related to Helicobacter pylori varies by population and geographic area. Our objective was to determine if the IL-1B -511 T>C and -31 C>T polymorphisms and H. pylori vacA genotypes are associated with risk of chronic gastritis and gastric ulcer in a Mexican population. Methods: We conducted endoscopic studies in 128 patients with symptoms of dyspepsia. We took two biopsies from the body, antrum, or ulcer edge from each patient, and classified our histopathological findings according to the Sydney System. H. pylori infection and vacA genotyping were accomplished via PCR from total DNA of the gastric biopsies. We confirmed the presence of anti-H. pylori serum IgG and IgM in 102 control subjects. In both case subjects and control subjects, the IL-1B -511 T>C polymorphism was genotyped by PCR-RFLPs and the IL-1B -31 C>T polymorphism was genotyped by pyrosequencing. Results: Sixty-two point seven (62.7%) of the 102 control subjects were H. pylori-seropositive. Among the case subjects, 100 were diagnosed with chronic gastritis and 28 with gastric ulcer. We found that 77% of the patients with chronic gastritis and 85.7% of the patients with gastric ulcer were H. pylori-positive. The predominant H. pylori genotype was vacA s1m1 (58.4%) and the most frequent subtype was vacA s1. The -511 TC, (rs16944 -511 T>C) genotype and the -511C allele were associated with chronic gastritis (OR = 3.1, 95% CI = 1.4-6.8 and OR = 3.0, 95% CI = 1.4-6.0, respectively). The subjects carrying -31T (rs1143627 -31 C>T) were found to be at a higher risk of having chronic gastritis (OR = 2.8, 95% CI = 1.3-5.8). The IL-1B -511C/-31T haplotype was associated with chronic gastritis (OR = 2.1, 95% CI = 1.2-3.8) but not with gastric ulcer. Conclusions: The H. pylori vacA genotypes identified herein were similar to those reported for other regions of Mexico. The vacA s1m1 genotype was not associated with gastric ulcer. In the southern Mexican population, the IL-1B -511C and -31T alleles and the -511C/-31T and -511T/-31T haplotypes are associated with increased risk of chronic gastritis and gastric ulcer.

11 March 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SCSayuri Itzel Clemente-Periván
Sayuri Itzel Clemente-Periván
Yazmín Gómez-GómezYazmín Gómez-Gómez
Yazmín Gómez-Gómez
MLMarco Antonio Leyva-Vázquez
Marco Antonio Leyva-Vázquez
ALAlfredo Lagunas-Martínez
Alfredo Lagunas-Martínez
Jorge Organista-NavaJorge Organista-Nava
Jorge Organista-Nava
BIBerenice Illades-Aguiar
Berenice Illades-Aguiar
Cervical cancer (CC) is the fourth most common type of cancer that affects women. Compared to other types of cancer, CC has a high mortality rate in women worldwide. Several factors contribute to the development of CC, but persistent high-risk human papillomavirus infection is the main etiologic agent associated with the development of CC. Moreover, several studies reported that alterations in the expression of transcription factors present in a small subpopulation of cells within tumors called cancer stem cells (CSCs), which contribute to the development of CC by promoting tumorigenicity and metastasis. These transcription factors affect self-renewal and maintenance of pluripotency and differentiation in stem cells. OCT3/4 belongs to the family of transcription factors with the POU domain. It consists of five exons and can be edited by alternative splicing into three main transcripts: OCT3/4A, OCT3/4B, and OCT3/4B1. The OCT3/4 expression in CSCs promotes carcinogenesis and the development of malignant tumors, and the loss of expression leads to the loss of self-renewal and proliferation and favors apoptosis. This review describes the main roles of OCT3/4 in CC and its importance in several biological processes that contribute to the development of CC and may serve as molecular targets to improve prognosis of CC.

3 May 2019 in Oncology Letters
Verified
Journal Article
Open access
PDF file
Jorge Organista-NavaJorge Organista-Nava
Jorge Organista-Nava
OGOlga Lilia Garibay-Cerdenares
Olga Lilia Garibay-Cerdenares
BIBerenice Illades-Aguiar
Berenice Illades-Aguiar
Yazmín Gómez-GómezYazmín Gómez-Gómez
Yazmín Gómez-Gómez
MLMarco Antonio Leyva‑Vázquez
Marco Antonio Leyva‑Vázquez
Cervical cancer is the fourth most common type of gynecological malignancy to affect females, worldwide. Although high‑risk human papillomavirus (HR‑HPV) infection is the primary etiologic agent associated with the development of cervical cancer, cancer stem cells (CSCs) also serve a prominent role in the development, metastasis, recurrence and prognosis of the disease. CSCs are a small subpopulation of cells that have the ability to self‑renew and are present in the majority of tumors, including cervical cancer. Studies describing the phenotype of cervical CSCs (CCSCs) vary in their definition of the expression pattern of principal biomarkers, including Musashi‑1, aldehyde dehydrogenase 1, Oct3/4, Sox2 and CD49f. However, these markers are not observed in all cancers, although several may be present in multiple tumor types. The present review describes the potential biomarkers of CSCs in cervical cancer. These CCSC biomarkers may serve as molecular targets to enhance the efficacy and reduce the side effects associated with chemotherapeutic treatment in HR‑HPV‑positive cervical cancer.

30 November 2015 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
GVGabriela Elizabeth Campos Viguri
Gabriela Elizabeth Campos Viguri
HJHilda Jiménez-Wences
Hilda Jiménez-Wences
OPOscar Peralta-Zaragoza
Oscar Peralta-Zaragoza
GTGricenda Torres-Altamirano
Gricenda Torres-Altamirano
DSDiana Guillermina Soto-Flores
Diana Guillermina Soto-Flores
GFGloria Fernández-Tilapa
Gloria Fernández-Tilapa
The aberrant expression of miR-23b is involved in the development and progression of cancer. The aim of this study was to evaluate the potential role of methylation in the silencing of miR-23b in cervical cancer cell lines and to determine its expression in stages of malignant progression and in cervical cancer tissues HPV16-positive. The methylation of the miR-23b promoter was determined in HeLa, SiHa, CaSki and C33A cells using a Human Cancer miRNA EpiTectMethyl II Signature PCR Array®. The cells were treated with 5-Aza-2′-deoxycytidine, and the expression of miR-23b, uPa, c-Met and Zeb1 was determined by qRT-PCR. miR-92a and GAPDH were used as controls. The expression of miR-23b was determined in cervical scrapes and biopsies of women without squamous intraepithelial lesions, with precursor lesions and with cervical cancer, all were HPV16-positive. The Fisher exact and Mann–Whitney tests were used to compare the differences of the expression of miR-23b, uPa, c-Met and Zeb1 among cell groups, and the difference among patients, respectively. The association between the expression of miR-23b and cervical cancer was determined by logistic regression with a confidence level of 95 %. A value of p < 0.05 was considered statistically significant. In C33A, HeLa and CaSki cells, methylation was associated with decreased expression of miR-23b. After treatment with 5-Aza-CdR, the expression of miR-23b increased in all cell lines and the expression of c-Met decreased in HeLa cells, while uPa and Zeb1 decreased in C33A and CaSki cells. In SiHa cells the expression of uPa, c-Met and Zeb1 increased. The expression of miR-23b decreased in relation to the increase in the severity of the lesion and was significantly lower in cervical cancer. In women with premalignant lesions HPV16-positive, decreased levels of miR-23b increased the risk of cervical cancer (OR = 36, 95 % CI = 6.7-192.6, p < 0.05). The results suggest that the expression of miR-23b is regulated by the methylation of its promoter and is possible that this microRNA influence the expression of uPa, c-Met and Zeb1 in cervical cancer cells lines. In women with premalignant lesions and cervical cancer infected with HPV16, the expression level of miR-23b agree with a tumor suppressor gene.

16 March 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
Adán Arizmendi-IzazagaAdán Arizmendi-Izazaga
Adán Arizmendi-Izazaga
Napoleón Navarro-TitoNapoleón Navarro-Tito
Napoleón Navarro-Tito
HJHilda Jiménez-Wences
Hilda Jiménez-Wences
Miguel Mendoza-CatalánMiguel Mendoza-Catalán
Miguel Mendoza-Catalán
DMDinorah Nashely Martínez-Carrillo
Dinorah Nashely Martínez-Carrillo
Julio Ortiz-OrtizJulio Ortiz-Ortiz
Julio Ortiz-Ortiz
Metabolic reprogramming is considered one of the hallmarks in cancer and is characterized by increased glycolysis and lactate production, even in the presence of oxygen, which leads the cancer cells to a process called “aerobic glycolysis” or “Warburg effect”. The E6 and E7 oncoproteins of human papillomavirus 16 (HPV 16) favor the Warburg effect through their interaction with a molecule that regulates cellular metabolism, such as p53, retinoblastoma protein (pRb), c-Myc, and hypoxia inducible factor 1α (HIF-1α). Besides, the impact of the E6 and E7 variants of HPV 16 on metabolic reprogramming through proteins such as HIF-1α may be related to their oncogenicity by favoring cellular metabolism modifications to satisfy the energy demands necessary for viral persistence and cancer development. This review will discuss the role of HPV 16 E6 and E7 variants in metabolic reprogramming and their contribution to developing and preserving the malignant phenotype of cancers associated with HPV 16 infection.